Previous Close | 0.9800 |
Open | 1.0000 |
Bid | 1.0000 x 800 |
Ask | 1.0300 x 1100 |
Day's Range | 0.9720 - 1.0400 |
52 Week Range | 0.9580 - 6.4000 |
Volume | |
Avg. Volume | 390,363 |
Market Cap | 43.17M |
Beta (5Y Monthly) | 3.40 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.7470 |
Earnings Date | Aug 01, 2022 - Aug 05, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 11.00 |
Subscribe to Yahoo Finance Plus to view Fair Value for AQST
Daniel Barber, current Chief Operating Officer of Aquestive, appointed as President and Chief Executive Officer and member of Board of DirectorsKeith Kendall, President and Chief Executive Officer and member of Board of Directors, will be leaving the CompanyKeith Kendall engaged as consultant to end of year to assist in management transition WARREN, N.J., May 17, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to solve patients’
We feel now is a pretty good time to analyse Aquestive Therapeutics, Inc.'s ( NASDAQ:AQST ) business as it appears the...
WARREN, N.J., May 10, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to solve patients' problems with current standards of care and provide transformative products to improve their lives, announced today that the management team will participate in the H.C. Wainwright Global Investment Conference from May 23rd to May 26th. The Aquestive team is scheduled to present on May 25th at 2:30 pm ET and will host investor meetings at the